Globe Newswire

Navios Maritime Holdings Inc.’s Tender Offer Deadline is midnight on June 7, 2024 to receive $4.75 in Cash for All Holders of ADSs (Series G & H) May 23, 2024 08:30AM

GRAND CAYMAN, Cayman Islands, May 23, 2024 (GLOBE NEWSWIRE) -- Navios Maritime Holdings Inc. (“Navios Holdings” or the “Company”) today provided a reminder of its continuing previously announced tender offer to purchase any and all outstanding Series G (CUSIP 63938Y100) and Series H (CUSIP 63938Y308) American Depositary Shares (the “Series G ADSs” and the “Series H ADSs”, together the “ADSs”) for cash pursuant to the terms previously described (the... (continue reading...)

Form 8.3 - [LOK'N STORE GROUP PLC - 22 05 2024] - (CGWL) May 23, 2024 08:30AM

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is... (continue reading...)

Navios Maritime Holdings Inc.’s Tender Offer Deadline is midnight on June 7, 2024 to receive $4.75 in Cash for All Holders of ADSs (Series G & H) May 23, 2024 08:30AM

GRAND CAYMAN, Cayman Islands, May 23, 2024 (GLOBE NEWSWIRE) -- Navios Maritime Holdings Inc. (“Navios Holdings” or the “Company”) today provided a reminder of its continuing previously announced tender offer to purchase any and all outstanding Series G (CUSIP 63938Y100) and Series H (CUSIP 63938Y308) American Depositary Shares (the “Series G ADSs” and the “Series H ADSs”, together the “ADSs”) for cash pursuant to the terms previously described (the... (continue reading...)

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences May 23, 2024 08:30AM

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company will present recently announced topline data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency... (continue reading...)

Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference May 23, 2024 08:30AM

MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am Central Time the same day via... (continue reading...)